Lexaria Bioscience Ownership
| LEXX Stock | USD 1.04 0.04 3.70% |
Shares in Circulation | First Issued 2005-12-31 | Previous Quarter 17.5 M | Current Value 18.3 M | Avarage Shares Outstanding 2.9 M | Quarterly Volatility 4.1 M |
Lexaria Stock Ownership Analysis
The book value of the company was now reported as 0.28. The company recorded a loss per share of 0.68. Lexaria Bioscience Corp last dividend was issued on the 12th of January 2021. The entity had 1:30 split on the 12th of January 2021. Lexaria Bioscience Corp. operates as a biotechnology company. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada. Lexaria Bioscience is traded on NASDAQ Exchange in the United States. To find out more about Lexaria Bioscience Corp contact Christopher Bunka at 250 765 6424 or learn more at https://lexariabioscience.com.Besides selling stocks to institutional investors, Lexaria Bioscience also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Lexaria Bioscience's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Lexaria Bioscience's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Lexaria Bioscience Quarterly Liabilities And Stockholders Equity |
|
About 6.0% of Lexaria Bioscience Corp are currently held by insiders. Unlike Lexaria Bioscience's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Lexaria Bioscience's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Lexaria Bioscience's insider trades
Lexaria Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Lexaria Bioscience is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Lexaria Bioscience Corp backward and forwards among themselves. Lexaria Bioscience's institutional investor refers to the entity that pools money to purchase Lexaria Bioscience's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bmo Capital Markets Corp. | 2025-06-30 | 14 K | Royal Bank Of Canada | 2025-06-30 | 7.3 K | Ubs Group Ag | 2025-06-30 | 6.1 K | Oakworth Capital Inc | 2025-06-30 | 5 K | Advisor Group Holdings, Inc. | 2025-06-30 | 2.2 K | Wells Fargo & Co | 2025-06-30 | 2 K | Tower Research Capital Llc | 2025-06-30 | 2 K | Federation Des Caisses Desjardins Du Quebec | 2025-06-30 | 382 | Bank Of America Corp | 2025-06-30 | 168 | Sabby Management Llc | 2025-06-30 | 1.2 M | Invenomic Capital Management, Lp | 2025-06-30 | 501.5 K |
Lexaria Bioscience Corp Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lexaria Bioscience insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lexaria Bioscience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Lexaria Bioscience insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Lexaria Bioscience Outstanding Bonds
Lexaria Bioscience issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Lexaria Bioscience Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Lexaria bonds can be classified according to their maturity, which is the date when Lexaria Bioscience Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Lexaria Stock Analysis
When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.